Autolus Therapeutics Company Leadership
Autolus Therapeutics employs about 647 people. The company is managed by 15 executives with a total tenure of roughly 1510 years, averaging almost 100.0 years of service per executive, having 43.13 employees per reported executive. Inspection of Autolus Therapeutics' management performance can provide insight into the company performance.
Autolus Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2028) % which means that it has lost $0.2028 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4997) %, meaning that it created substantial loss on money invested by shareholders. Autolus Therapeutics' management efficiency ratios could be used to measure how well Autolus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Autolus Therapeutics Workforce Comparison
Autolus Therapeutics is rated second in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 2,053. Autolus Therapeutics totals roughly 647 in number of employees claiming about 32% of equities under Health Care industry.
Autolus Therapeutics Notable Stakeholders
An Autolus Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Autolus Therapeutics often face trade-offs trying to please all of them. Autolus Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Autolus Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MBBS MD | Senior Founder | Profile | |
| Christopher Vann | Senior COO | Profile | |
| Robert MD | Executive Director | Profile | |
| Olivia Manser | Director Relations | Profile | |
| David Brochu | Senior Officer | Profile | |
| Chris Williams | Senior Development | Profile | |
| Robert Dolski | Chief Officer | Profile | |
| Lucinda Crabtree | Chief Officer | Profile | |
| Christopher Williams | Chief Officer | Profile | |
| Alexander Swan | Senior Officer | Profile | |
| Christian Itin | CEO Director | Profile | |
| Brent Rice | Chief VP | Profile | |
| Alex Driggs | Senior Secretary | Profile | |
| Matthias MD | Senior Officer | Profile | |
| ACA BEcon | Advisor | Profile |
Autolus Therapeutics Workforce Analysis
Traditionally, organizations such as Autolus Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Autolus Therapeutics within its industry.Autolus Therapeutics Manpower Efficiency
Return on Autolus Therapeutics Manpower
| Revenue Per Employee | 15.6K | |
| Revenue Per Executive | 674.7K | |
| Net Loss Per Employee | 341.1K | |
| Net Loss Per Executive | 14.7M | |
| Working Capital Per Employee | 927.6K | |
| Working Capital Per Executive | 40M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Tools for Autolus Stock
When running Autolus Therapeutics' price analysis, check to measure Autolus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Autolus Therapeutics is operating at the current time. Most of Autolus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Autolus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Autolus Therapeutics' price. Additionally, you may evaluate how the addition of Autolus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |